Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals.

Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH.

Public Health Rep. 2005 Jan-Feb;120(1):84-8.

2.
3.

Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.

Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA.

JAMA Intern Med. 2014 May;174(5):721-9. doi: 10.1001/jamainternmed.2014.601.

4.

Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community.

Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL.

Clin Infect Dis. 2004 Jun 15;38(12):1754-60. Epub 2004 May 26.

PMID:
15227623
5.

Intensive case management before and after prison release is no more effective than comprehensive pre-release discharge planning in linking HIV-infected prisoners to care: a randomized trial.

Wohl DA, Scheyett A, Golin CE, White B, Matuszewski J, Bowling M, Smith P, Duffin F, Rosen D, Kaplan A, Earp J.

AIDS Behav. 2011 Feb;15(2):356-64. doi: 10.1007/s10461-010-9843-4.

6.

Accessing antiretroviral therapy following release from prison.

Baillargeon J, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, Paar DP.

JAMA. 2009 Feb 25;301(8):848-57. doi: 10.1001/jama.2009.202.

7.

Antiretroviral treatment regimen outcomes among HIV-infected prisoners.

Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL.

HIV Clin Trials. 2007 Jul-Aug;8(4):205-12.

8.

Effect of directly observed antiretroviral therapy compared to self-administered antiretroviral therapy on adherence and virological outcomes among HIV-infected prisoners: a randomized controlled pilot study.

White BL, Golin CE, Grodensky CA, Kiziah CN, Richardson A, Hudgens MG, Wohl DA, Kaplan AH.

AIDS Behav. 2015 Jan;19(1):128-36. doi: 10.1007/s10461-014-0850-8.

9.

Evaluation of Routine HIV Opt-Out Screening and Continuum of Care Services Following Entry into Eight Prison Reception Centers--California, 2012.

Lucas KD, Eckert V, Behrends CN, Wheeler C, MacGowan RJ, Mohle-Boetani JC.

MMWR Morb Mortal Wkly Rep. 2016 Feb 26;65(7):178-81. doi: 10.15585/mmwr.mm6507a3.

10.

Predictors of reincarceration and disease progression among released HIV-infected inmates.

Baillargeon J, Giordano TP, Harzke AJ, Spaulding AC, Wu ZH, Grady JJ, Baillargeon G, Paar DP.

AIDS Patient Care STDS. 2010 Jun;24(6):389-94. doi: 10.1089/apc.2009.0303.

11.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

12.

Enrollment in outpatient care among newly released prison inmates with HIV infection.

Baillargeon JG, Giordano TP, Harzke AJ, Baillargeon G, Rich JD, Paar DP.

Public Health Rep. 2010 Jan-Feb;125 Suppl 1:64-71.

13.

Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT Trial.

Wohl DA, Golin CE, Knight K, Gould M, Carda-Auten J, Groves JS, Napravnik S, Cole SR, White BL, Fogel C, Rosen DL, Mugavaro MJ, Pence BW, Flynn PM.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):81-90. doi: 10.1097/QAI.0000000000001337.

PMID:
28277487
14.
15.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
16.

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D.

JAMA. 2001 Jul 11;286(2):196-207.

PMID:
11448283
17.

Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression.

Hatano H, Vogel S, Yoder C, Metcalf JA, Dewar R, Davey RT Jr, Polis MA.

AIDS. 2000 Jul 7;14(10):1357-63.

PMID:
10930150
18.

Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.

Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, Sirisanthana V.

Clin Infect Dis. 2005 Jul 1;41(1):100-7. Epub 2005 May 24.

PMID:
15937769
19.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
20.

High mortality among male HIV-infected patients after prison release: ART is not enough after incarceration with HIV.

Huber F, Merceron A, Madec Y, Gadio G, About V, Pastre A, Coupez I, Adenis A, Adriouch L, Nacher M.

PLoS One. 2017 Apr 28;12(4):e0175740. doi: 10.1371/journal.pone.0175740. eCollection 2017.

Supplemental Content

Support Center